Trial site
Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont
- 14running trials
- 5closed trials
The trials here
What the 19 trials at this site are about, from their registry records.
- Conditions
- Obesity5 trials
- Ulcerative colitis3 trials
- Crohn's disease2 trials
- Dilated cardiomyopathy2 trials
- Heart failure2 trials
- Melanoma2 trials
- Type 2 diabetes2 trials
- Alzheimer disease1 trial
- Antiphospholipid syndrome1 trial
- Bladder cancer1 trial
- Chronic kidney disease1 trial
- Coronary artery disease1 trial
- and 11 more
- Phase
- Phase 312 trials
- Phase 23 trials
- Phase 2/32 trials
- Phase 11 trial
- Status
- Active, not recruiting6 trials
- Completed5 trials
- Recruiting4 trials
- Not yet recruiting3 trials
- Enrolling by invitation1 trial
- Lead sponsor
- Eli Lilly and Company7 trials
- Kardigan, Inc.2 trials
- Alimentiv Inc.1 trial
- Amgen1 trial
- Bayer1 trial
- and 7 more
Running trials
Recruiting
Recruiting
Recruiting
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Recruiting
Recruiting
Recruiting
Recruiting
Enrolling by invitation
Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial)
Active, not recruiting
Active, not recruiting
Active, not recruiting
Active, not recruiting
Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.
Active, not recruiting
Active, not recruiting
Riociguat in Children With Pulmonary Arterial Hypertension (PAH)
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
- Obesity3 recruiting
- Crohn's disease2 recruiting
- Dilated cardiomyopathy2 recruiting
- Antiphospholipid syndrome1 recruiting
- Bladder cancer1 recruiting
- Dermatomyositis and polymyositis (myositis)1 recruiting
- Heart failure1 recruiting
- Immune thrombocytopenia (ITP)1 recruiting
- Ulcerative colitis1 recruiting
Closed trials
Completed
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight
Completed
Completed
Completed
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL)
Completed
Site data: ClinicalTrials.govUpdated 17 Nov 2026